DelveInsight’s ‘Essential Thrombocythemia (ET) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Essential Thrombocythemia, historical and forecasted epidemiology as well as the Essential Thrombocythemia trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Essential Thrombocythemia Understanding
According to the MPN Research Foundation, Essential Thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increased number of platelets in the blood. The overproduction (megakaryocytic hyperplasia) of platelet-forming cells, called “megakaryocytes,” in the marrow results in the release of too many platelets into the blood.
The term “essential” indicates that the increase in platelets is an inherent problem of the blood cell production in the bone marrow and “Thrombocythemia” refers to an excess of platelets in the blood. Also, the increased platelet count may result in the blockage in blood vessels (thrombus), splenomegaly, and hemorrhagic episodes. Most cases of ET are not inherited, and it arises from gene mutations that occur in early blood-forming cells after conception. However, in very rare cases, ET is inherited in an autosomal dominant pattern and known as familial Essential Thrombocythemia.
The typical pattern of ET onset is bimodal, with one peak occurring during young adulthood in females and the other peak occurring between the ages of 50–70 years in both males and females. The incidence of ET is around 1.5–2 times higher in females as compared to males.
Essential Thrombocythemia (ET) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Essential Thrombocythemia (ET), Total Prevalence of Essential Thrombocythemia Based on Symptoms, Gender-specific Diagnosed Prevalence of Essential Thrombocythemia, Age-specific Diagnosed Prevalence of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia based on Risk, and Gene Mutation Specific Prevalence of Essential Thrombocythemia scenario of ET in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Essential Thrombocythemia (ET) Detailed Epidemiology Segmentation
• As per DelveInsight’s analysis, the total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM was found to be 232,688 in 2017. The estimates higher prevalence of Essential Thrombocythemia (ET) in the United States with 142,635 cases in 2017.
• According to DelveInsight’s analysis, it has been observed that ET is mostly diagnosed in the age group of 60-80.
• Among EU5, France shows a higher prevalence of ET followed by Germany and the UK, Italy, and Spain respectively.
• Japan accounts second among the 7MM in terms of prevalent cases with 19,946 cases among the 7MM.
Scope of the Report
• The report covers the descriptive overview of Essential Thrombocythemia (ET), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Essential Thrombocythemia (ET).
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Population of Essential Thrombocythemia (ET), Total Prevalence of Essential Thrombocythemia Based on Symptoms, Gender-specific Diagnosed Prevalence of Essential Thrombocythemia, Age-specific Diagnosed Prevalence of Essential Thrombocythemia, Prevalence of Essential Thrombocythemia based on Risk, and Gene Mutation Specific Prevalence of Essential Thrombocythemia
Report Highlights
• 11-Year Forecast of Essential Thrombocythemia (ET)
• 7MM Coverage
• Total Prevalent Cases of Essential Thrombocythemia (ET),
• Total Prevalent Population of Essential Thrombocythemia (ET) based on Symptoms
• Total Gender-specific Diagnosed Prevalence of Essential Thrombocythemia (ET)
• Total Age-specific Diagnosed Prevalence of Essential Thrombocythemia (ET)
• Total Prevalence of Essential Thrombocythemia (ET) based on Risk
• Gene Mutation Specific Prevalence of Essential Thrombocythemia (ET)
Key Questions Answered
• What is the disease risk, burden and unmet needs of Essential Thrombocythemia (ET)?
• What is the historical Essential Thrombocythemia (ET) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Essential Thrombocythemia (ET) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Essential Thrombocythemia (ET)?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Essential Thrombocythemia (ET) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The Essential Thrombocythemia (ET) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Essential Thrombocythemia (ET) epidemiology forecast.
• The Essential Thrombocythemia (ET) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Essential Thrombocythemia (ET) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
- 1. Key Insights
- 2. Executive Summary of Essential Thrombocythemia (ET)
- 3. Disease Background and Overview: Essential Thrombocythemia (ET)
- 3.1. Introduction
- 3.2. Symptoms
- 3.3. Causes
- 3.4. Risk Factors
- 3.5. Pathogenesis
- 3.6. Diagnosis of ET
- 3.6.1. 2016 World Health Organization Diagnostic Criteria for Essential Thrombocythemia
- 3.6.2. Diagnostic criteria of essential thrombocythemia by the British Committee for Standards in Haematology
- 3.6.3. International Prognostic Score for Thrombosis in Essential Thrombocythemia
- 3.6.4. Diagnostic algorithm
- 4. Case Reports
- 4.1. A Rare Case of Triple-Negative Essential Thrombocythemia in a Young Postsplenectomy Patient: A Diagnostic Challenge
- 4.2. Case Report: Headache in a Postpartum Patient with Essential Thrombocytosis
- 4.3. Essential Thrombocythemia in a young man treated for myocardial infarction
- 4.4. Next-generation sequencing redefines a triple-negative Essential Thrombocythemia as double-positive with rare mutations on JAK2 V617 and MPL W515 hotspots
- 4.5. JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia
- 5. Epidemiology and Patient Population
- 5.1. Key Findings
- 5.2. Epidemiology Methodology
- 5.3. Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM
- 6. United States Epidemiology
- 6.1. Assumptions and Rationale
- 6.2. Total Prevalent Population of Essential Thrombocythemia (ET) in the United States
- 6.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the United States
- 6.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in the United States
- 6.5. Age-specific Diagnosed Prevalence of ET in the United States
- 6.6. Prevalence of ET Cases Based on Risk in the United States
- 6.7. Gene Mutation specific Prevalence of ET in the United States
- 7. EU5 Epidemiology
- 7.1. Germany Epidemiology
- 7.1.1. Assumptions and Rationale
- 7.1.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Germany
- 7.1.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany
- 7.1.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Germany
- 7.1.5. Age-specific Diagnosed Prevalence of ET in Germany
- 7.1.6. Prevalence of ET Cases Based on Risk in Germany
- 7.1.7. Gene Mutation specific Prevalence of ET in Germany
- 7.2. France Epidemiology
- 7.2.1. Assumptions and rationale
- 7.2.2. Total Prevalent Population of Essential Thrombocythemia (ET) in France
- 7.2.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France
- 7.2.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in France
- 7.2.5. Age-specific Diagnosed Prevalence of ET in France
- 7.2.6. Prevalence of ET Cases Based on Risk in France
- 7.2.7. Gene Mutation specific Prevalence of ET in France
- 7.3. Italy Epidemiology
- 7.3.1. Assumptions and Rationale
- 7.3.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Italy
- 7.3.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy
- 7.3.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Italy
- 7.3.5. Age-specific Diagnosed Prevalence of ET in Italy
- 7.3.6. Prevalence of ET Cases Based on Risk in Italy
- 7.3.7. Gene Mutation specific Prevalence of ET in Italy
- 7.4. Spain Epidemiology
- 7.4.1. Assumptions and Rationale
- 7.4.2. Total Prevalent Population of Essential Thrombocythemia (ET) in Spain
- 7.4.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain
- 7.4.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Spain
- 7.4.5. Age-specific Diagnosed Prevalence of ET in Spain
- 7.4.6. Prevalence of ET Cases Based on Risk in Spain
- 7.4.7. Gene Mutation specific Prevalence of ET in Spain
- 7.5. United Kingdom Epidemiology
- 7.5.1. Assumptions and Rationale
- 7.5.2. Total Prevalent Population of Essential Thrombocythemia (ET) in the UK
- 7.5.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK
- 7.5.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in the UK
- 7.5.5. Age-specific Diagnosed Prevalence of ET in the UK
- 7.5.6. Prevalence of ET Cases Based on Risk in the UK
- 7.5.7. Gene Mutation specific Prevalence of ET in the UK
- 8. Japan Epidemiology
- 8.1. Assumptions and Rationale
- 8.2. Total Prevalent Population of Essential Thrombocythemia (ET) Japan
- 8.3. Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan
- 8.4. Gender-specific Prevalence of Essential Thrombocythemia (ET) in Japan
- 8.5. Age-specific Diagnosed Prevalence of ET in Japan
- 8.6. Prevalence of ET Cases Based on Risk in Japan
- 8.7. Gene Mutation specific Prevalence of ET in Japan
- 9. KOL Views
- 10. Appendix
- 11. Bibliography
- 11.1. Report Methodology
- 12. DelveInsight Capabilities
- 13. Disclaimer
- 14. About DelveInsight
- List of Tables
- Table 1 Summary of Essential Thrombocythemia (ET), Market, Epidemiology and Key Events (2017–2030)
- Table 2 Distribution of mutation in ET patients
- Table 3 WHO criteria for the diagnosis of ET
- Table 4 Proposed diagnostic criteria for essential thrombocythemia
- Table 5 Significant risk factors for thrombosis in patients with WHO-defined ET and associated prognostic scores
- Table 6 Risk group and prognosis
- Table 7 Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM (2017–2030)
- Table 8 Total Prevalent Population of Essential Thrombocythemia (ET) in the US (2017–2030)
- Table 9 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the US (2017–2030)
- Table 10 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the US (2017–2030)
- Table 11 Age-specific Diagnosed Prevalence of ET in the US (2017–2030)
- Table 12 Prevalence of ET Based on Risk in the US (2017–2030)
- Table 13 Gene Mutation specific Prevalence of ET in the US (2017–2030)
- Table 14 Total Prevalent Population of Essential Thrombocythemia (ET) in Germany (2017–2030)
- Table 15 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany (2017–2030)
- Table 16 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Germany (2017–2030)
- Table 17 Age-specific Diagnosed Prevalence of ET in Germany (2017–2030)
- Table 18 Prevalence of ET Based on Risk in Germany (2017–2030)
- Table 19 Gene Mutation specific Prevalence of ET in Germany (2017–2030)
- Table 20 Total Prevalent Population of Essential Thrombocythemia (ET) in France (2017–2030)
- Table 21 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France (2017–2030)
- Table 22 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in France (2017–2030)
- Table 23 Age-specific Diagnosed Prevalence of ET in France (2017–2030)
- Table 24 Prevalence of ET Based on Risk in France (2017–2030)
- Table 25 Gene Mutation specific Prevalence of ET in France (2017–2030)
- Table 26 Total Prevalent Population of Essential Thrombocythemia (ET) in Italy (2017–2030)
- Table 27 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy (2017–2030)
- Table 28 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Italy (2017–2030)
- Table 29 Age-specific Diagnosed Prevalence of ET in Italy (2017–2030)
- Table 30 Prevalence of ET Based on Risk in Italy (2017–2030)
- Table 31 Gene Mutation specific Prevalence of ET in Italy (2017–2030)
- Table 32 Total Prevalent Population of Essential Thrombocythemia (ET) in Spain (2017–2030)
- Table 33 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain (2017–2030)
- Table 34 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Spain (2017–2030)
- Table 35 Age-specific Diagnosed Prevalence of ET in Spain (2017–2030)
- Table 36 Prevalence of ET Based on Risk in Spain (2017–2030)
- Table 37 Gene Mutation specific Prevalence of ET in Spain (2017–2030)
- Table 38 Total Prevalent Population of Essential Thrombocythemia (ET) in the UK (2017–2030)
- Table 39 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK (2017–2030)
- Table 40 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the UK (2017–2030)
- Table 41 Age-specific Diagnosed Prevalence of ET in the UK (2017–2030)
- Table 42 Prevalence of ET Based on Risk in the UK (2017–2030)
- Table 43 Gene Mutation specific Prevalence of ET in the UK (2017–2030)
- Table 44 Total Prevalent Population of Essential Thrombocythemia (ET) in Japan (2017–2030)
- Table 45 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan (2017–2030)
- Table 46 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Japan (2017–2030)
- Table 47 Age-specific Diagnosed Prevalence of ET in Japan (2017–2030)
- Table 48 Prevalence of ET Based on Risk in Japan (2017–2030)
- Table 49 Gene Mutation specific Prevalence of ET in Japan (2017–2030)
- List of Figures
- Figure 1 Laboratory Features of Polycythemia Vera, Essential Thrombocythemia, and Idiopathic Myelofibrosis
- Figure 2 Common symptoms of ET
- Figure 3 Gene mutations in ET
- Figure 4 Role of JAK2 in pathway signaling and erythropoietin binding, stem-cell differentiation, and development of homozygosity for the V617F mutation
- Figure 5 Diagnostic algorithm for essential thrombocythemia
- Figure 6 Total Prevalent Population of Essential Thrombocythemia (ET) in the 7MM (2017–2030)
- Figure 7 Total Prevalent Population of Essential Thrombocythemia (ET) in the US (2017–2030)
- Figure 8 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the US (2017–2030)
- Figure 9 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the US (2017–2030)
- Figure 10 Age-specific Diagnosed Prevalence of ET in the US (2017–2030)
- Figure 11 Prevalence of ET Based on Risk in the US (2017–2030)
- Figure 12 Gene Mutation specific Prevalence of ET in the US (2017–2030)
- Figure 13 Total Prevalent Population of Essential Thrombocythemia (ET) in Germany (2017–2030)
- Figure 14 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Germany (2017–2030)
- Figure 15 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Germany (2017–2030)
- Figure 16 Age-specific Diagnosed Prevalence of ET in Germany (2017–2030)
- Figure 17 Prevalence of ET Based on Risk in Germany (2017–2030)
- Figure 18 Gene Mutation specific Prevalence of ET in Germany (2017–2030)
- Figure 19 Total Prevalent Population of Essential Thrombocythemia (ET) in France (2017–2030)
- Figure 20 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in France (2017–2030)
- Figure 21 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in France (2017–2030)
- Figure 22 Age-specific Diagnosed Prevalence of ET in France (2017–2030)
- Figure 23 Prevalence of ET Based on Risk in France (2017–2030)
- Figure 24 Gene Mutation specific Prevalence of ET in France (2017–2030)
- Figure 25 Total Prevalent Population of Essential Thrombocythemia (ET) in Italy (2017–2030)
- Figure 26 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Italy (2017–2030)
- Figure 27 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Italy (2017–2030)
- Figure 28 Age-specific Diagnosed Prevalence of ET in Italy (2017–2030)
- Figure 29 Prevalence of ET Based on Risk in Italy (2017–2030)
- Figure 30 Gene Mutation specific Prevalence of ET in Italy (2017–2030)
- Figure 31 Total Prevalent Population of Essential Thrombocythemia (ET) in Spain (2017–2030)
- Figure 32 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Spain (2017–2030)
- Figure 33 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Spain (2017–2030)
- Figure 34 Age-specific Diagnosed Prevalence of ET in Spain (2017–2030)
- Figure 35 Prevalence of ET Based on Risk in Spain (2017–2030)
- Figure 36 Gene Mutation specific Prevalence of ET in Spain (2017–2030)
- Figure 37 Total Prevalent Population of Essential Thrombocythemia (ET) in the UK (2017–2030)
- Figure 38 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in the UK (2017–2030)
- Figure 39 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in the UK (2017–2030)
- Figure 40 Age-specific Diagnosed Prevalence of ET in the UK (2017–2030)
- Figure 41 Prevalence of ET Based on Risk in the UK (2017–2030)
- Figure 42 Gene Mutation specific Prevalence of ET in the UK (2017–2030)
- Figure 43 Total Prevalent Population of Essential Thrombocythemia (ET) in Japan (2017–2030)
- Figure 44 Prevalence of Essential Thrombocythemia (ET) Based on Symptoms in Japan (2017–2030)
- Figure 45 Gender-Specific Prevalence of Essential Thrombocythemia (ET) in Japan (2017–2030)
- Figure 46 Age-specific Diagnosed Prevalence of ET in Japan (2017–2030)
- Figure 47 Prevalence of ET Based on Risk in Japan (2017–2030)
- Figure 48 Gene Mutation specific Prevalence of ET in Japan (2017–2030)
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook